Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
RESEARCH TOOLSreports
Kiniksa Pharmaceuticals (KNSA) Stock Price & Analysis
409 Followers
KNSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.02 - $22.09
Previous Close$20.26
Volume344.71K
Average Volume (3M)394.41K
Market Cap
$1.44B
Enterprise Value$1.24B
Total Cash (Recent Filing)$206.37M
Total Debt (Recent Filing)$12.26M
Price to Earnings (P/E)187.1
Beta-0.02
Next Earnings
Jul 31, 2024EPS Estimate
<$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding70,940,145
10 Day Avg. Volume417,645
30 Day Avg. Volume394,409
Standard Deviation0.17
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.42
Price to Sales (P/S)3.02
Price to Cash Flow (P/CF)83.40
P/FCF Ratio83.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.91
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda-107.00
Forecast
1Y Price Target
$30.67Price Target Upside51.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Kiniksa Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentClinical validation for CD40 as a target has been reinforced, providing a strong basis for future studies in conditions such as Sjogren's Syndrome.
Financial Health And Company OutlookWith a healthy capital position and a cash runway extending into at least 2027, the company exhibits solid financial stability, underpinning its capacity for sustained growth and development.
Product Adoption And Sales MomentumArcalyst is gaining traction as a preventive and maintenance treatment, with an increasing number of repeated prescribers signaling its growing acceptance in the medical community.
Bears Say
Clinical Trial ResultsKPL-404 phase 2 trial results mixed.
Drug Development UncertaintyPhase 2 abiprubart proof-of-concept data show signal but path forward contingent upon more data.
Drug EfficacyCohort 4 in rheumatoid arthritis just missed statistical significance on the primary endpoint of change from baseline in DAS28-CRP at Week 12.
---
Ownership Overview
16.84% Insiders
17.05% Mutual Funds
19.75% Other Institutional Investors
46.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $13.02 and its highest was $22.09 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Currently, no data Available
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 82 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Apr 23, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.082 by -$0.168.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is <$0.01.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 40,305,405 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.082. Following the earnings report the stock price went up 3.392%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Among the largest hedge funds holding Kiniksa Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Kiniksa Pharmaceuticals’s shares valued at 51M.
---
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.67 (51.91% Upside)
$30.67 (51.91% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 432.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.18%
12-Months-Change
Fundamentals
Return on Equity
2.10%
Trailing 12-Months
Asset Growth
17.34%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
---
KNSA Stock 12 Month Forecast
Average Price Target
$30.67
▲(51.91% Upside)
Technical Analysis
Seres Therapeutics
―
Ultragenyx Pharmaceutical
―
Mersana Therapeutics
―
Vertex Pharmaceuticals
―
Best Analysts Covering KNSA
1 Year
1 Year Success Rate
9/11 ratings generated profit
1 Year Average Return
+21.38%
assigned a buy rating 16 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +21.38% per trade.
---